IDEXX Laboratories Inc (IDXX) - Total Assets
Based on the latest financial reports, IDEXX Laboratories Inc (IDXX) holds total assets worth $3.39 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore IDEXX Laboratories Inc (IDXX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
IDEXX Laboratories Inc - Total Assets Trend (1991–2025)
This chart illustrates how IDEXX Laboratories Inc's total assets have evolved over time, based on quarterly financial data. See IDEXX Laboratories Inc (IDXX) net assets for net asset value and shareholders' equity analysis.
IDEXX Laboratories Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
IDEXX Laboratories Inc's total assets of $3.39 Billion consist of 40.0% current assets and 60.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.4% |
| Accounts Receivable | $693.19 Million | 20.7% |
| Inventory | $377.76 Million | 11.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $109.84 Million | 3.3% |
| Goodwill | $414.00 Million | 12.4% |
Asset Composition Trend (1991–2025)
This chart illustrates how IDEXX Laboratories Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IDEXX Laboratories Inc (IDXX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IDEXX Laboratories Inc's current assets represent 40.0% of total assets in 2025, a decrease from 69.3% in 1991.
- Cash Position: Cash and equivalents constituted 5.4% of total assets in 2025, down from 24.4% in 1991.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 1991.
- Asset Diversification: The largest asset category is accounts receivable at 20.7% of total assets.
IDEXX Laboratories Inc Competitors by Total Assets
Key competitors of IDEXX Laboratories Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.41 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
China | CN¥1.76 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
SCOPE FLUIDICS SA ZY-10
F:S84
|
Germany | €195.94 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$563.12K |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
IDEXX Laboratories Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.12 | 1.16 | 1.54 |
| Quick Ratio | 0.82 | 0.81 | 1.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $154.22 Million | $181.40 Million | $349.42 Million |
IDEXX Laboratories Inc - Advanced Valuation Insights
This section examines the relationship between IDEXX Laboratories Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.28 |
| Latest Market Cap to Assets Ratio | 13.08 |
| Asset Growth Rate (YoY) | 1.7% |
| Total Assets | $3.35 Billion |
| Market Capitalization | $43.83 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values IDEXX Laboratories Inc's assets at a significant premium (13.08x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: IDEXX Laboratories Inc's assets grew by 1.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for IDEXX Laboratories Inc (1991–2025)
The table below shows the annual total assets of IDEXX Laboratories Inc from 1991 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.35 Billion | +1.74% |
| 2024-12-31 | $3.29 Billion | +1.03% |
| 2023-12-31 | $3.26 Billion | +18.68% |
| 2022-12-31 | $2.75 Billion | +12.70% |
| 2021-12-31 | $2.44 Billion | +6.22% |
| 2020-12-31 | $2.29 Billion | +25.22% |
| 2019-12-31 | $1.83 Billion | +19.20% |
| 2018-12-31 | $1.54 Billion | -10.28% |
| 2017-12-31 | $1.71 Billion | +11.94% |
| 2016-12-31 | $1.53 Billion | +3.78% |
| 2015-12-31 | $1.47 Billion | +6.56% |
| 2014-12-31 | $1.38 Billion | +12.49% |
| 2013-12-31 | $1.23 Billion | +11.50% |
| 2012-12-31 | $1.10 Billion | +7.06% |
| 2011-12-31 | $1.03 Billion | +14.90% |
| 2010-12-31 | $897.14 Million | +10.96% |
| 2009-12-31 | $808.53 Million | +5.63% |
| 2008-12-31 | $765.44 Million | +9.01% |
| 2007-12-31 | $702.18 Million | +25.49% |
| 2006-12-31 | $559.56 Million | +14.04% |
| 2005-12-31 | $490.68 Million | -4.58% |
| 2004-12-31 | $514.24 Million | -1.46% |
| 2003-12-31 | $521.88 Million | +25.25% |
| 2002-12-31 | $416.65 Million | +11.67% |
| 2001-12-31 | $373.11 Million | +11.11% |
| 2000-12-31 | $335.80 Million | -6.78% |
| 1999-12-31 | $360.20 Million | -7.76% |
| 1998-12-31 | $390.50 Million | +3.58% |
| 1997-12-31 | $377.00 Million | +0.83% |
| 1996-12-31 | $373.90 Million | +19.65% |
| 1995-12-31 | $312.50 Million | +156.78% |
| 1994-12-31 | $121.70 Million | +24.18% |
| 1993-12-31 | $98.00 Million | +22.96% |
| 1992-12-31 | $79.70 Million | +109.19% |
| 1991-12-31 | $38.10 Million | -- |
About IDEXX Laboratories Inc
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urin… Read more